BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 1192421)

  • 1. Microcytotoxicity assays of tumor immunity in patients with bronchogenic carcinoma correlated with clinical status.
    Pierce GE; DeVald B
    Cancer Res; 1975 Dec; 35(12):3577-84. PubMed ID: 1192421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotype and function of natural killer cells in patients with bronchogenic carcinoma.
    LeFever AV; Funahashi A
    Cancer Res; 1991 Oct; 51(20):5596-601. PubMed ID: 1655257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxic activity of lymphocytes to bronchogenic carcinoma cells in patients with lung cancer.
    Yasumoto K; Ohta M; Nomoto K
    Gan; 1976 Aug; 67(4):505-11. PubMed ID: 1030675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Demonstration of antibodies against tumor-associated antigens in the serum patients with bronchogenic carcinoma using anticomplement immunofluorescence on xenotransplants of human tumors].
    Stiller-Winkler R; Stark M; Idel H
    Zentralbl Bakteriol Mikrobiol Hyg B; 1985 Mar; 180(4):381-93. PubMed ID: 2988233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Demonstration of immune reactions against cultured hamartoma cells with lymphocytes from patients with bronchogenic carcinoma.
    Pierce GE; Allingham R; Bell JW
    Surg Forum; 1972; 23(0):89-91. PubMed ID: 4671035
    [No Abstract]   [Full Text] [Related]  

  • 6. Cytotoxicity tests against cultured human lung cancer cells with autologous lymphocytes activated in vitro by mitomycin C-treated tumor monolayers in the presence of T-cell growth factor.
    Kimura H; Yamaguchi Y; Kadoyama C; Sato N; Fujisawa T
    Jpn J Clin Oncol; 1983 Mar; 13(1):3-13. PubMed ID: 6300483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphocyte cytotoxicity against allogeneic cultured cells in gynecologic malignancy.
    Arata T; Momozaki F; Kazuta M; Yamamoto H; Sekiba K
    Acta Med Okayama; 1979 Jun; 33(3):197-204. PubMed ID: 158947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cytotoxicity of lymphocytes against autologous cultured primary lung cancer cells in relation to histological type and clinical stage].
    Kimura H; Yamaguchi Y; Kadoyama C; Matsumoto A
    Gan To Kagaku Ryoho; 1986 Jun; 13(6):2175-81. PubMed ID: 3013100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of anticancer therapy of lymphocyte cytotoxicity in lung cancer patients.
    Manabe H; Yasumoto K; Ohta M; Toyohira K; Nomoto K
    Gan; 1977 Aug; 68(4):477-82. PubMed ID: 357239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diminished lymphocyte responses to phytohemagglutinin in lung cancer.
    Hadjipetrou-Kourounakis L; Tsougranis A
    Biochem Exp Biol; 1980; 16(4):357-64. PubMed ID: 6285942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Serum beta 2-microglobulin and carcinoembryonic antigen in patients with bronchogenic carcinoma].
    Cha RJ; Chen SJ; Xiao CZ; Liang XL; Zhou NK
    Zhonghua Zhong Liu Za Zhi; 1986 Sep; 8(5):342-4. PubMed ID: 3552534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Delayed immunity in bronchial cancer: lymphocyte activation in culture with phytohemagglutinins and tuberculin PPD compared with the skin response to tubercular antigens].
    Piacentini G; Ferrari S; Megale C; Ippoliti F
    Boll Ist Sieroter Milan; 1973; 52(3):230-6. PubMed ID: 4762779
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunoprofile studies for patients with bronchogenic carcinoma. I. Correlation of pretherapy studies with survival.
    Liebler GA; Concannon JP; Magovern GJ; Dalbow MH; Hodgson SE
    J Thorac Cardiovasc Surg; 1977 Oct; 74(4):506-18. PubMed ID: 302883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of human lymphocytes on cultured normal and malignant cells.
    Pierce GE; DeVald BL
    Cancer Res; 1975 Jul; 35(7):1830-9. PubMed ID: 805664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [T-Lymphocyte shifts in patients with melanoma and bronchogenic carcinoma (author's transl)].
    Pichler WJ; Stingl G; Micksche M; Neumann H; Knapp W
    Wien Klin Wochenschr; 1976 Nov; 88(21):707-9. PubMed ID: 1087506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytostatic activity of peripheral blood monocytes against bronchogenic carcinoma cells in patients with lung cancer.
    Yanagawa E; Yasumoto K; Manabe H; Nagano N; Hirota N; Ohta M; Hattori T; Nomoto K; Azuma I; Yamamura Y
    Gan; 1979 Aug; 70(4):533-9. PubMed ID: 229054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunologic assays in lung cancer. Skin tests, lymphocyte blastogenesis, and rosette-forming cell count.
    Brugarolas A; Han T; Takita H; Minowada J
    N Y State J Med; 1973 Mar; 73(6):747-50. PubMed ID: 4510958
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of human sera on reactivity of lymphocytes in microcytotoxicity assays.
    Pierce GE; DeVald BL
    Cancer Res; 1975 Oct; 35(10):2729-37. PubMed ID: 1157047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunocytology of cancer.
    Davidsohn I; Ni LY
    Acta Cytol; 1970 May; 14(5):276-82. PubMed ID: 4935158
    [No Abstract]   [Full Text] [Related]  

  • 20. Generation of monoclonal antibodies against human lung squamous cell carcinoma and adenocarcinoma using mice rendered tolerant to normal human lung.
    Hanai N; Shitara K; Yoshida H
    Cancer Res; 1986 Sep; 46(9):4438-43. PubMed ID: 3731100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.